Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)
China · Delayed Price · Currency is CNY 56.04
+0.61 (1.10%)
Apr 8, 2026, 3:04 PM CST
SHE:300347 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 6,713 | 6,474 | 7,289 | 7,002 | 5,187 |
Other Revenue | 119.47 | 129.04 | 94.93 | 83.93 | 26.17 |
| 6,833 | 6,603 | 7,384 | 7,085 | 5,214 | |
Revenue Growth (YoY) | 3.48% | -10.58% | 4.21% | 35.91% | 63.32% |
Cost of Revenue | 4,960 | 4,359 | 4,539 | 4,277 | 2,943 |
Gross Profit | 1,873 | 2,244 | 2,845 | 2,808 | 2,271 |
Selling, General & Admin | 960.56 | 944.45 | 837.52 | 780.02 | 676.88 |
Research & Development | 257.64 | 238.39 | 261.56 | 234.62 | 211.83 |
Other Operating Expenses | 31.71 | 22.2 | 19.15 | 7.17 | 12.5 |
Operating Expenses | 1,265 | 1,235 | 1,155 | 1,046 | 926.93 |
Operating Income | 608.47 | 1,009 | 1,690 | 1,763 | 1,344 |
Interest Expense | -90.56 | -141.24 | -119.9 | -83.18 | -24.91 |
Interest & Investment Income | 448.94 | 256.86 | 568.02 | 330.09 | 568.16 |
Currency Exchange Gain (Loss) | -16.95 | 18.02 | 2.61 | 20.13 | -11.83 |
Other Non Operating Income (Expenses) | -9.26 | -6.59 | -3.32 | -6.88 | -1.48 |
EBT Excluding Unusual Items | 940.64 | 1,137 | 2,138 | 2,023 | 1,874 |
Impairment of Goodwill | -20.28 | -5 | -29.16 | - | - |
Gain (Loss) on Sale of Investments | 42.26 | -501.69 | 352.77 | 535.86 | 1,815 |
Gain (Loss) on Sale of Assets | 3.65 | 3.56 | -0.19 | -0.09 | -0.53 |
Asset Writedown | -0.22 | - | - | -0.45 | - |
Other Unusual Items | 37.16 | 31.05 | 27.24 | 27.1 | -3.96 |
Pretax Income | 1,003 | 664.46 | 2,489 | 2,585 | 3,685 |
Income Tax Expense | 198.16 | 216.63 | 338.61 | 313.65 | 292.86 |
Earnings From Continuing Operations | 805.06 | 447.83 | 2,150 | 2,272 | 3,392 |
Minority Interest in Earnings | 82.83 | -42.69 | -125.08 | -265.17 | -517.54 |
Net Income | 887.89 | 405.14 | 2,025 | 2,007 | 2,874 |
Net Income to Common | 887.89 | 405.14 | 2,025 | 2,007 | 2,874 |
Net Income Growth | 119.15% | -79.99% | 0.91% | -30.19% | 64.26% |
Shares Outstanding (Basic) | 856 | 863 | 865 | 865 | 868 |
Shares Outstanding (Diluted) | 856 | 863 | 865 | 866 | 871 |
Shares Change (YoY) | -0.83% | -0.22% | -0.07% | -0.62% | 9.01% |
EPS (Basic) | 1.04 | 0.47 | 2.34 | 2.32 | 3.31 |
EPS (Diluted) | 1.04 | 0.47 | 2.34 | 2.32 | 3.30 |
EPS Growth | 120.99% | -79.94% | 0.86% | -29.70% | 50.69% |
Free Cash Flow | 903.72 | 740.45 | 836.68 | 908.9 | 1,055 |
Free Cash Flow Per Share | 1.06 | 0.86 | 0.97 | 1.05 | 1.21 |
Dividend Per Share | 0.126 | 0.300 | 0.568 | 0.550 | 0.500 |
Dividend Growth | -58.00% | -47.18% | 3.27% | 10.00% | 66.67% |
Gross Margin | 27.41% | 33.99% | 38.53% | 39.64% | 43.55% |
Operating Margin | 8.91% | 15.29% | 22.89% | 24.88% | 25.77% |
Profit Margin | 13.00% | 6.14% | 27.42% | 28.32% | 55.13% |
Free Cash Flow Margin | 13.23% | 11.21% | 11.33% | 12.83% | 20.24% |
EBITDA | 820.3 | 1,215 | 1,876 | 1,921 | 1,458 |
EBITDA Margin | 12.01% | 18.40% | 25.40% | 27.12% | 27.97% |
D&A For EBITDA | 211.84 | 205.22 | 185.06 | 158.69 | 114.71 |
EBIT | 608.47 | 1,009 | 1,690 | 1,763 | 1,344 |
EBIT Margin | 8.91% | 15.29% | 22.89% | 24.88% | 25.77% |
Effective Tax Rate | 19.75% | 32.60% | 13.61% | 12.13% | 7.95% |
Revenue as Reported | 6,833 | 6,603 | 7,384 | 7,085 | 5,214 |
Advertising Expenses | 13.05 | 14.1 | 19.97 | 19.24 | 14.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.